Results 281 to 290 of about 1,467,646 (404)

Non-affinity platform for processing knob-into-hole bispecific antibody. [PDF]

Bioresour Bioprocess
Wang X, Li M, Li M, Hong H, Gao K, Zhao P.   +5 more
europepmc   +1 more source

Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study

Cancer, Volume 131, Issue 14, 15 July 2025.
Abstract Background Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple‐class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results from the phase 1/2 MonumenTAL‐1 study (ClinicalTrials.gov identifiers NCT03399799 and NCT04634552).
Carolina Schinke, Cyrille Touzeau, Albert Oriol, María‐Victoria Mateos, Don Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Sacheeta Bathija, Eva G. Katz, Katharine S. Gries, Michela Campagna, Tara Masterson, Brandi W. Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Chalmer Tomlinson, Philippe Moreau, Jesús San‐Miguel, Paula Rodríguez‐Otero, Ajai Chari   +21 more
wiley   +1 more source

Bispecific antibody targets and therapies in multiple myeloma. [PDF]

Front Immunol
Rees M, Abdallah N, Yohannan B, Gonsalves WI.   +3 more
europepmc   +1 more source

In vitro and in vivo properties of a dimeric bispecific single‐chain antibody IgG‐fusion protein for depletion of CCR2⁺ target cells in mice

, 2005
Martin Schneider, Hilke Brühl, Alexandra Wechselberger, Josef Cihak, M. Stangassinger, Detlef Schlöndorff, Matthias Mack   +6 more
openalex   +1 more source

Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells [PDF]

, 2011
Hitoe Torisu‐Itakura, Hans F. Schoellhammer, Myung‐Shin Sim, Reiko F. Irie, Susanne Hausmann, Tobias Raum, Patrick A. Baeuerle, Donald L. Morton   +7 more
openalex   +1 more source

NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. [PDF]

JACC Basic Transl Sci
Delfos L, Depuydt MAC, Chemaly M, Coyle S, Schaftenaar FH, van Santbrink PJ, Lindenbergh PP, Bernabé Kleijn MNA, Costello C, Power CA, Coll R, Peace A, Gregory-Ksander M, Foks AC, Kuiper J, McGilligan V, Bot I.   +16 more
europepmc   +1 more source

Bispecific Antibody Pretargeting for Improving Cancer Imaging and Therapy

, 2005
Robert M. Sharkey
openalex   +2 more sources

Synthesis and Evaluation of an Anti-MLC1 × Anti-CD90 Bispecific Antibody for Targeting and Retaining Bone-Marrow-Derived Multipotent Stromal Cells in Infarcted Myocardium [PDF]

, 2011
C. William Gundlach, Amy R. Caivano, Maria da Graça Cabreira-Hansen, Amir Gahremanpour, Wells S. Brown, Yi Zheng, Bradley W. McIntyre, James T. Willerson, Richard A. F. Dixon, Emerson C. Perin, Darren G. Woodside   +10 more
openalex   +1 more source

Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody‐Dependent Cytotoxicity

Angewandte Chemie, Volume 137, Issue 27, July 1, 2025.
This study presents novel macrocyclic peptides with low nanomolar affinity for CD59, an immunomodulatory cell surface receptor associated with human disease. Crystallographic and structure‐activity relationship (SAR) studies reveal peptide CP‐06 mimics the binding of biologically relevant CD59 interaction partners. Dimeric and lipidated CP‐06 analogues
Jasmine K. Bickel, Ammar. I. S. Ahmed, Aidan B. Pidd, Rhodri M. Morgan, Tom E. McAllister, Sam Horrell, Emma C. Couves, Hemavathi Nagaraj, Edward J. Bartlett, Kamel El Omari, Akane Kawamura, Doryen Bubeck, Edward W. Tate   +12 more
wiley   +2 more sources

Bioorthogonal Reaction of o-Quinone with Furan-2(3H)-One for Site-Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes. [PDF]

Adv Sci (Weinh)
Chen H, Xu Z, Bao Y, Shiri F, Yuan D, Hu Y, Li B, Zeng B, Li X, Kong H, Wang Z, Lau WC, Lin Z, Xia J.   +13 more
europepmc   +1 more source